Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: activity relationship

Installation of sites for metabolism in the lead compound PHA-767408 was the key focus of the IKK-2 inhaled program. This paper reports our efforts to identify a novel series of aminopyridinecarboxamide-based IKK-2 inhibitors, which display low nanomolar potency against IKK-2 with long duration of a...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2011-02, Vol.19 (3), p.1242-1255
Main Authors: Xie, Jin, Poda, Gennadiy I, Hu, Yiding, Chen, Natalie X, Heier, Richard F, Wolfson, Serge G, Reding, Matthew T, Lennon, Patrick J, Kurumbail, Ravi G, Selness, Shaun R, Li, Xiong, Kishore, Nandini N, Sommers, Cynthia D, Christine, Lori, Bonar, Sheri L, Venkatraman, Neetu, Mathialagan, Sumathy, Brustkern, Sarah J, Huang, Horng-Chih
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Installation of sites for metabolism in the lead compound PHA-767408 was the key focus of the IKK-2 inhaled program. This paper reports our efforts to identify a novel series of aminopyridinecarboxamide-based IKK-2 inhibitors, which display low nanomolar potency against IKK-2 with long duration of action (DOA), and metabolically labile to phase I and/or phase II metabolizing enzymes with potential capability for multiple routes of clearance. Several compounds have demonstrated their potential usefulness in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
ISSN:0968-0896
DOI:10.1016/j.bmc.2010.12.027